Some Investors Pass on Eagerly Awaited Pharma IPO
A number of investors who won the right to buy shares in one of China’s leading pharmaceutical firms upon its eagerly awaited mainland initial public offering (IPO) have decided not to buy the shares after all.
WuXi AppTec Co. Ltd. — one of three companies spun off from WuXi PharmaTech after that company delisted from the New York Stock Exchange in 2015 — is to list in its home country’s Shanghai Stock Exchange this week. WuXi AppTec has been the subject of intense attention as market observers think that the price of the firm’s shares will surge upon listing, so the fact that it failed to secure some buyers came as a surprise.
- 1China Cancels Trade Talks With U.S.
- 2Bad Bank’s New Boss Begins by Erasing Fallen Predecessor’s Legacy
- 3Rape Investigation for Internet Tycoon Richard Liu Wraps Up
- 4Merck Slashes Key Cancer Drug Price for China
- 5 Caixin Explains: Why Urbanites are Choosing Pickles and Instant Noodles Over Avocados and Starbucks
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas